Literature DB >> 29404391

RAD6 promotes chemoresistance in ovarian cancer.

David W Clark1, Chinnadurai Mani1, Komaraiah Palle1.   

Abstract

Mortality in ovarian cancer is predominantly due to acquired chemoresistance and tumor recurrence. UBIQUITIN CONJUGATING ENZYME E2 or RAD6 expression increases in cell lines and patient tumors in response to platinum-based chemotherapy and promotes both activation of DNA damage response pathways and expression of stemness genes and a stem cell-like phenotype driving ovarian cancer chemoresistance.

Entities:  

Keywords:  DNA repair; RAD6; cancer stem cells; chemoresistance; ovarian cancer

Year:  2017        PMID： 29404391      PMCID： PMC5791863          DOI： 10.1080/23723556.2017.1392403

Source DB:  PubMed          Journal:  Mol Cell Oncol        ISSN： 2372-3556


  9 in total

1.  Rad6 plays a role in transcriptional activation through ubiquitylation of histone H2B.

Authors:  Cheng-Fu Kao; Cory Hillyer; Toyoko Tsukuda; Karl Henry; Shelley Berger; Mary Ann Osley
Journal:  Genes Dev       Date:  2004-01-15       Impact factor: 11.361

2.  RAD6-dependent DNA repair is linked to modification of PCNA by ubiquitin and SUMO.

Authors:  Carsten Hoege; Boris Pfander; George-Lucian Moldovan; George Pyrowolakis; Stefan Jentsch
Journal:  Nature       Date:  2002-09-12       Impact factor: 49.962

3.  RAD6B overexpression confers chemoresistance: RAD6 expression during cell cycle and its redistribution to chromatin during DNA damage-induced response.

Authors:  Alex Lyakhovich; Malathy P V Shekhar
Journal:  Oncogene       Date:  2004-04-15       Impact factor: 9.867

4.  Synthesis and in vitro anticancer evaluation of some 4,6-diamino-1,3,5-triazine-2-carbohydrazides as Rad6 ubiquitin conjugating enzyme inhibitors.

Authors:  Hend Kothayer; Sebastian M Spencer; Kaushlendra Tripathi; Andrew D Westwell; Komaraiah Palle
Journal:  Bioorg Med Chem Lett       Date:  2016-03-02       Impact factor: 2.823

Review 5.  The role of RAD6 in recombinational repair, checkpoints and meiosis via histone modification.

Authors:  John C Game; Sophia B Chernikova
Journal:  DNA Repair (Amst)       Date:  2009-02-18

6.  Rad6B is a positive regulator of beta-catenin stabilization.

Authors:  Malathy P V Shekhar; Brigitte Gerard; Robert J Pauley; Bart O Williams; Larry Tait
Journal:  Cancer Res       Date:  2008-03-15       Impact factor: 12.701

7.  Rad6 upregulation promotes stem cell-like characteristics and platinum resistance in ovarian cancer.

Authors:  Ranganatha R Somasagara; Kaushlendra Tripathi; Sebastian M Spencer; David W Clark; Reagan Barnett; Lavanya Bachaboina; Jennifer Scalici; Rodney P Rocconi; Gary A Piazza; Komaraiah Palle
Journal:  Biochem Biophys Res Commun       Date:  2015-12-08       Impact factor: 3.575

8.  RAD6 promotes DNA repair and stem cell signaling in ovarian cancer and is a promising therapeutic target to prevent and treat acquired chemoresistance.

Authors:  R R Somasagara; S M Spencer; K Tripathi; D W Clark; C Mani; L Madeira da Silva; J Scalici; H Kothayer; A D Westwell; R P Rocconi; K Palle
Journal:  Oncogene       Date:  2017-08-14       Impact factor: 9.867

9.  Rad18 confers hematopoietic progenitor cell DNA damage tolerance independently of the Fanconi Anemia pathway in vivo.

Authors:  Yang Yang; Jonathan C Poe; Lisong Yang; Andrew Fedoriw; Siddhi Desai; Terry Magnuson; Zhiguo Li; Yuri Fedoriw; Kimi Araki; Yanzhe Gao; Satoshi Tateishi; Stefanie Sarantopoulos; Cyrus Vaziri
Journal:  Nucleic Acids Res       Date:  2016-02-15       Impact factor: 16.971
  9 in total
  2 in total

1.  Expression of CD44+/CD24-, RAD6 and DDB2 on chemotherapy response in ovarian Cancer: A prospective flow cytometry study.

Authors:  Unedo Hence Markus Sihombing; Gatot Purwoto; Supriadi Gandamihardja; Alida R Harahap; Primariadewi Rustamadji; Aria Kekalih; Retno Widyawati; Dzicky Rifqi Fuady
Journal:  Gynecol Oncol Rep       Date:  2022-06-03

Review 2.  The Molecular Basis of Ubiquitin-Conjugating Enzymes (E2s) as a Potential Target for Cancer Therapy.

Authors:  Xiaodi Du; Hongyu Song; Nengxing Shen; Ruiqi Hua; Guangyou Yang
Journal:  Int J Mol Sci       Date:  2021-03-26       Impact factor: 5.923
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.